MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $8.02, down 6.85% on the session, giving a market capitalisation of $41.2M. On trailing twelve-month figures it carries a trailing P/E of -3.58, a net margin of -5512.5%. Its beta of 0.45 implies it has historically moved less than the broad market.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
MiNK Therapeutics, Inc. is most often compared with the following Healthcare names: